EMERYVILLE, Calif.,
Sept. 1, 2020 /PRNewswire/ -- Amyris,
Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company in
Clean Health and Beauty markets through its consumer brands, and a
top supplier of sustainable and natural ingredients, today
announced that it has successfully scaled up the commercial
production of Cannabigerol (CBG) leveraging its industrial
fermentation process capability.
Amyris expects to deliver about one ton of high purity CBG
through fermentation as an alternative to the traditional
production method of extraction from the Cannabis sativa L. plant.
First commercial revenue from the sale of this molecule is
anticipated this year as an ingredient in applications that are
excluded from Amyris's current collaboration agreements. Product
margins are anticipated to operate above the current industry
average realized by existing publicly traded CBD suppliers.
CBG is the precursor from which all other cannabinoids are
synthesized and is often referred to as the "stem cell" of
cannabinoids. CBG is a non-psychoactive cannabinoid and presents
significant therapeutic potential, making it a subject of great
interest for researchers and consumers alike. Amyris's fermentation
process is well-positioned to result in the lowest cost CBG with
higher purity (no THC), which is expected to unlock CBG's
adoption.
Early testing on skin models demonstrates advantaged performance
of CBG for various topical indications over CBD. Furthermore, the
combination of CBG with Amyris's sugar cane-based squalene provides
some of the highest efficacy results for topical applications.
Early studies indicate that CBG has the potential to deliver better
efficacy than CBD in about one third of current CBD topical
applications.
"Amyris's biotechnology platform continues to demonstrate its
capability to engineer yeast to create and produce differentiated
high value products. This molecule was developed from initial
target to full scale production in less than nine months," said
Eduardo Alvarez, Chief Operating
Officer.
"We are very excited about the disruptive nature of this
molecule for potential skin care applications and through flavor
and fragrance partnerships and our cosmetic distribution channels,"
commented John Melo, President and
Chief Executive Officer. "This is the tenth product we deliver at
scale through our fermentation platform, and reaffirms the
continued expansion of our portfolio and our growth ambition to
provide sustainably and economically produced natural
ingredients."
About Amyris
Amyris (Nasdaq: AMRS) is a science and
technology leader in the research, development and production of
sustainable ingredients for the Clean Health & Beauty and
Flavors & Fragrances markets. Amyris uses an impressive array
of exclusive technologies, including state-of-the-art machine
learning, robotics and artificial intelligence. Our ingredients are
included in over 3,000 products from the world's top brands,
reaching more than 200 million consumers. Amyris is proud to own
three consumer brands - all built around its No Compromise® promise
of clean ingredients: Biossance™ clean beauty skincare, Pipette™
clean baby skincare and Purecane™, a zero-calorie sweetener
naturally derived from sugarcane. For more information, please
visit www.amyris.com.
Forward-Looking Statements
This release contains
forward-looking statements, and any statements other than
statements of historical fact could be deemed to be forward-looking
statements. These forward-looking statements include, among other
things, statements regarding the fermentation method of cannabinoid
production, the timing of commercial revenue expectations, the cost
for production of cannabigerol production, the purity profile of
the cannabigerol product, efficacy results in topical applications
of Amyris's cannabigerol product, and future timing of cannabinoid
production. These statements are based on management's current
expectations, and actual results and future events may differ
materially due to risks and uncertainties, including risks related
to Amyris's liquidity and ability to fund operating and capital
expenses, risks related to potential delays or failures in
development, production and commercialization of products, risks
related to Amyris's reliance on third parties, and other risks
detailed from time to time in filings Amyris makes with the
Securities and Exchange Commission, including Annual Reports on
Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on
Form 8-K. Amyris disclaims any obligation to update information
contained in these forward-looking statements, whether as a result
of new information, future events, or otherwise.
Amyris, the Amyris logo, No Compromise, Biossance, Pipette, and
Purecane are trademarks or registered trademarks of Amyris, Inc. in
the U.S. and/or other countries.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/amyris-scales-first-fermentation-based-cannabinoid-301121470.html
SOURCE Amyris, Inc.